论文部分内容阅读
目的:观察D+/R+肾移植术后人群应用更昔洛韦预防巨细胞病毒感染的疗效与安全性。方法:我院2003年5月至2011年11月期间D+/R+同种异体肾移植患者93例,肾移植术后预防性应用更昔洛韦,对移植后1年内巨细胞病毒的感染率、感染发生的时间及有症状的CMV发病率进行以及用药后不良事件进行分析。结果:在D+/R+肾移植人群中预防性使用更昔洛韦后的感染率为28%,有症状的CMV发病率4.3%,病毒血症的平均感染时间为231.3 d,严重不良事件发生率为45.1%。结论:在D+/R+肾移植术后患者中预防性更昔洛韦能够预防CMV感染并且延长CMV初次感染时间,使D+/R+肾移植患者获益。
Objective: To observe the efficacy and safety of ganciclovir in the prevention of cytomegalovirus infection in D + / R + renal transplant recipients. Methods: 93 cases of D + / R + allograft in our hospital from May 2003 to November 2011 were treated with ganciclovir prophylactically after renal transplantation. The infection rate of cytomegalovirus within 1 year after transplantation, The timing of the infection and the incidence of symptomatic CMV were followed and adverse events after treatment were analyzed. RESULTS: The rate of infection with ganciclovir prophylaxis in D + / R + kidney transplant recipients was 28%, the incidence of symptomatic CMV was 4.3%, and the mean duration of infection with viremia was 231.3 days. The incidence of serious adverse events Is 45.1%. CONCLUSIONS: Prophylactic ganciclovir can prevent CMV infection and prolong the time of primary CMV infection in patients after D + / R + kidney transplantation, benefiting patients with D + / R + kidney transplantation.